Recent Studies on Thimerosal and Autism

A selection of studies/articles re: the neurotoxicity of thimerosal

A Scandal of Epidemic Proportions: The media and government on autism - asleep at the wheel or in bed with the drug companies?

The Thimerosal/SV40 Connection  - Public Health's Ongoing Scandal

Recommended list - Autism/mercury

Autism: A Unique Type of Mercury Poisoning

Thimerosal - Harmless Vaccine Preservative Or Just Another Toxic Organic Mercury Compound?

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11834460&dopt=Abstract

 
Environ Health Perspect 2002 Feb;110 Suppl 1:11-23 Related Articles, Books, LinkOut
Click here to read 
The three modern faces of mercury.

Clarkson TW.

Department of Environmental Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA. tcw30@aol.com

The three modern "faces" of mercury are our perceptions of risk from the exposure of billions of people to methyl mercury in fish, mercury vapor from amalgam tooth fillings, and ethyl mercury in the form of thimerosal added as an antiseptic to widely used vaccines. In this article I review human exposure to and the toxicology of each of these three species of mercury. Mechanisms of action are discussed where possible. Key gaps in our current knowledge are identified from the points of view both of risk assessment and of mechanisms of action.

Publication Types:
  • Review
  • Review, Tutorial


PMID: 11834460 [PubMed - indexed for MEDLINE]

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12051779&dopt=Abstract

 
Environ Res 2002 May;89(1):1-11 Related Articles, Books, LinkOut
Click here to read 
Neurodevelopmental investigations among methylmercury-exposed children in French Guiana.

Cordier S, Garel M, Mandereau L, Morcel H, Doineau P, Gosme-Seguret S, Josse D, White R, Amiel-Tison C.

Unit 170-Epidemiological and Statistical Research on Environment and Health, National Institute of Health and Medical Research (INSERM), 94807 Villejuif Cedex, France.

French Guiana, like its neighbors, suffers from environmental pollution with methylmercury from gold mining activities, and Amerindian communities are particularly affected. A neurological and a neurospsychological evaluation were carried out in children of three Amerindian communities with various levels of pollution: 156 children from the Upper Maroni (high exposure), 69 from Camopi on the Oyapock river (median exposure), and 153 from Awala on the Atlantic coast (low exposure). Exposure to methylmercury was measured by determination of total mercury in the hair of the children and their mothers (geometric mean, 12.7 microg/g in Upper Maroni). No major neurologic signs were observed in the children examined. After adjustment for potential confounders, we found a dose-dependent association between maternal hair mercury level and increased deep tendon reflexes, poorer coordination of the legs, and decreased performance in the Stanford-Binet Copying score, which measures visuospatial organization. In this last test, the frequency of rotation errors was high in the 5-6 years age group and increased with mercury exposure. These associations depended on the sex of child and were stronger among boys. The interpretation of these results is limited mainly by the cross-sectional design of the study. It identifies specific neurological and neuropsychological deficits, in some cases modulated by sex, which are consistent with known targets of mercury neurotoxicity. 2002 Elsevier Science (USA)

PMID: 12051779 [PubMed - in process]
 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11368282&dopt=Abstract

 
Drugs 2001;61(5):565-72 Related Articles, Books, LinkOut

Vaccines without thiomersal: why so necessary, why so long coming?

van't Veen AJ.

Department of Dermatology and Venereology, Erasmus University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands.

The inorganic mercurial thiomersal (merthiolate) has been used as an effective preservative in numerous medical and non-medical products since the early 1930s. Both the potential toxicity of thiomersal and sensitisation to thiomersal in relation to the application of thiomersal-containing vaccines and immunoglobulins, especially in children, have been debated in the literature. The very low thiomersal concentrations in pharmacological and biological products are relatively non-toxic, but probably not in utero and during the first 6 months of life. The developing brain of the fetus is most susceptible to thiomersal and, therefore, women of childbearing age, in particular, should not receive thiomersal-containing products. Definitive data of doses at which developmental effects occur are not available. Moreover, revelation of subtle effects of toxicity needs long term observation of children. The ethylmercury radical of the thiomersal molecule appears to be the prominent sensitiser. The prevalence of thiomersal hypersensitivity in mostly selected populations varies up to 18%, but higher figures have been reported. The overall exposure to thiomersal differs considerably between countries. In many cases a positive routine patch test to thiomersal should be considered an accidental finding without or, probably more accurately, with low clinical relevance. In practice, some preventive measures can be taken with respect to thiomersal hypersensitivity. However, with regard to the debate on primary sensitisation during childhood and renewed attention for a reduction of children's exposure to mercury from all sources, the use of thiomersal should preferably be eliminated or at least be reduced. In 1999 the manufacturers of vaccines and immunoglobulins in the US and Europe were approached with this in mind. The potential toxicity in children seems to be of much more concern to them than the hidden sensitising properties of thiomersal. In The Netherlands, unlike many other countries, the exposure to thiomersal from pharmaceutical sources has already been reduced. Replacement of thiomersal in all products should have a high priority in all countries.

Publication Types:
  • Review
  • Review, Tutorial


PMID: 11368282 [PubMed - indexed for MEDLINE]

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11686639&dopt=Abstract

 
Environ Int 2001 Oct;27(4):285-90 Related Articles, Books, LinkOut

Mercury pollution in the Tapajos River basin, Amazon: mercury level of head hair and health effects.

Harada M, Nakanishi J, Yasoda E, Pinheiro MC, Oikawa T, de Assis Guimaraes G, da Silva Cardoso B, Kizaki T, Ohno H.

Department of Social Welfare Studies, Kumamoto Gakuen University, Japan.

There is increasing concern about the potential neurotoxic effects of exposure to methylmercury for the 6 million people living in the Amazon, even in regions situated far away from the gold mines (garimpos), considered to be the major source of mercury pollution. In November 1998, a spot investigation on mercury contamination was conducted in three fishing villages (Barreiras, Rainha, and Sao Luiz do Tapajos) on the Tapajos River, an effluent of the Amazon, situated several hundred kilometers downstream from the gold-mining areas. A total of 132 fishermen and their families volunteered for the current study. As was anticipated, the total mercury levels in the head hair collected from the fishing villages were relatively high (14.1-20.8 ppm on the average) and the number of subjects with a high total mercury level over 10 ppm (the least upper bound of a normal value) was 103 (78.0%) in total, along with various symptoms, thereby suggesting wide mercury contamination in the Tapajos River basin. Moreover, in view of the absence of other diseases (e.g., alcoholism or malaria), a high intake of fish containing a methylmercury level, and high hair mercury levels in addition to the various symptoms such as sensory disturbance (especially glove-and-stocking type, which is characteristic of Minamata disease), tremor, failure in two-point discrimination, and slight balancing failure, several subjects examined were diagnosed with mild Minamata disease. The findings obtained suggest, thus, that the mercury pollution in the Amazon should be crucially observed for head hair mercury level and health in a much broader region.

PMID: 11686639 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11483816&dopt=Abstract

 
Pediatrics 2001 Aug;108(2):466-7 Related Articles, Books, LinkOut

Comment in:

Click here to read 
Balancing risks and benefits: Primum non nocere is too simplistic.

Halsey NA, Goldman L.

Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of PublicHealth, Baltimore, MD 21205, USA. nhalsey@jhsph.edu

PMID: 11483816 [PubMed - indexed for MEDLINE]

Balancing Risks and Benefits: Primum non nocere Is Too Simplistic

COMMENTARY By:
Neal A. Halsey, MD
Institute for Vaccine Safety
Johns Hopkins University Bloomberg School of Public Health
Baltimore, MD 21205
Lynn Goldman, MD
Department of Environmental Health Sciences
Johns Hopkins University Bloomberg School of Public Health
Baltimore, MD 21205

      [This material contains technical language. PEDIATRICS Vol. 108 No. 2
August 2001, pp. 466-467.]

      The commentary by Seal and Daum entitled “What Happened to Primum non nocere?”1 [“First, do no harm”] that appeared in the May 2001 issue of Pediatrics criticized the July 1999 recommendation of the American Academy of Pediatrics (AAP) and US Public Health Service (USPHS) to delay the birth dose of hepatitis B vaccine for infants born to hepatitis B surface antigen (HBsAg)-negative women to reduce infant exposure to thimerosal.2 The commentary contains incorrect statements and oversimplifies the complex process of balancing multiple risks and benefits when formulating vaccine policy as summarized in the excellent article by Feudtner and Marcuse3 in the same issue. Some professionals had difficulty understanding the need for the July 1999 recommendations because they didn’t fully understand the risks from organomercury exposure and the amounts of ethylmercury present in
vaccines. Several developments in the past 2 years have reinforced the wisdom of the recommendations made in July 1999. 

     Seal and Daum stated that methylmercury “might” be harmful to the developing fetal central nervous system. Methylmercury is neurotoxic at all ages, and the developing fetal brain is at least 10-fold more sensitive than
the adult brain.4

      They also incorrectly stated that “no data existed that implicated ethylmercury” as a cause of neurotoxicity. As reviewed by Ball et al,5 ethylmercury from thimerosal has caused significant neurotoxicity in infants, children, and adults. Such data were available at the time of the 1999 recommendations and several references were included in the more complete AAP statement on this issue.6

      On July 11, 2000, the Committee on the Toxicological Effects of Methylmercury of the National Research Council (NRC) proposed a resolution of the conflict regarding the appropriate reference dose (RfD) for
methylmercury exposure.7 The Committee proposed an RfD of 0.1 µg/kg/d, the same dose that had been used by the Environmental Protection Agency. The Committee used recently generated data from the Faroe Islands study as the basis for the RfD. The Committee estimated that 60 000 children are born each year in the United States with unsafe levels of methylmercury in their bodies. More recently, the Centers for Disease Control and Prevention found
that levels of mercury in women of childbearing age in the United States are at least as high as, and perhaps higher than, the NRC estimates, which were based on modeled exposures.8

      The adverse effects from intrauterine low-dose methylmercury exposure are not detected early in life and include alterations in attention, fine motor, and cognitive function that fit in the overall category of learning impairment. The NRC noted that all sources of mercury must be considered when determining the need for interventions. For infants born to women who have high levels of methylmercury, the possible additive effects from subsequent exposure to ethylmercury (from thimerosal) are not known but are of potential concern, especially given that so many children start out life with mercury levels that exceed recommended guidelines. Moreover, the potential exposures to ethylmercury from thimerosal alone were in excess of 0.1 µg/kg/d at the time that doses were administered, and such bolus administration would likely result in higher blood levels and subsequent transmission to the brain.9

      Based on the NRC report, on January 12, 2001, the Food and Drug Administration (FDA) recommended that pregnant women, women of childbearing age, infants, and very young children not consume swordfish, shark,
tilefish, and mackerel because of unacceptably high levels of methylmercury.10 Swordfish contains an average of 1 part per million of methylmercury, or 28 µg/oz. If a meal is 3 oz, a 55- to 70-kg woman should not consume 84 µg of methylmercury at any point during pregnancy. How would vaccine advisory groups be perceived today if recommendations had not been made to reduce the potential for administration of up to 75 µg of ethylmercury to infants in the first 6 to 8 weeks of age? Most of the exposures to ethylmercury in vaccines were avoidable. The AAP and the USPHS had a responsibility to inform physicians and the public of new information about risks of exposure to mercury from all sources at levels once thought to be safe, and to provide guidance regarding the reduction of exposures from thimerosal.

      Seal and Daum implied that exposures to thimerosal were known to be safe in July 1999; however, ethylmercury had not been studied in animals or humans from the standpoint of toxicity to the developing brain. In particular, there were no epidemiologic studies of intellectual development, learning disabilities, or other adverse effects that might be associated with ethylmercury exposure in utero or early in life. Preliminary studies from West Coast health maintenance organizations revealed dose-related evidence of increased risk of learning disabilities, delayed speech, and other abnormalities, but no such relationship was found in an East Coast population.11 Additional studies are being planned by the National Institutes of Health and the Centers for Disease Control and Prevention to determine if there were any toxic effects from thimerosal exposure.

      Another misundertanding by Seal and Daum was that manufacturers and the FDA were well on their way to removing thimerosal from vaccines for infants in July 1999. Without strong advocacy from the AAP and USPHS, there would not have been the remarkably rapid removal of thimerosal from vaccines administered to children. As of February 2001, manufacturers were no longer producing vaccines that contain thimerosal as a preservative for diphtheria, tetanus, and acellular pertussis vaccines combined (DTaP), Haemophilus influenzae, or hepatitis B vaccines that are used in infants.

      One of us (N.A.H.) is the principal author of the 1992 AAP statement establishing the recommendation for universal hepatitis B immunization of infants, and I am well aware of the important benefits of administering
hepatitis B vaccine beginning at birth.12 The recommendation to delay the birth dose for low-risk infants in July 1999 was not taken lightly by the AAP or the USPHS. Although initiating vaccination at birth provides a safety shield against errors in communication about maternal HBsAg status, we cannot depend on this backup because some providers will continue to administer the first dose of hepatitis B vaccine in combination with other vaccines beginning at 6 to 8 weeks of age for infants born to HBsAg-negative mothers. Extra efforts must be made to ensure screening of all women during pregnancy and to minimize errors in communication from obstetric providers to providers of care for newborns.

      The process of making sound immunization policy requires careful balancing of many factors as eloquently summarized by Feudtner and Marcuse.3 To maintain public confidence in vaccines, we must ensure the public that
safety is taken very seriously, and, when indicated, timely actions are taken to reduce potential risks. Vaccine manufacturers and the FDA should be applauded for the rapid changes in manufacturing and marketing practices
that led to an elimination of the use of thimerosal as a preservative in routine vaccines for infants.

FOOTNOTES
Received for publication May 17, 2001; accepted Jun 15, 2001.
Address correspondence to Neal A. Halsey, MD, Johns Hopkins University
Bloomberg School of Public Health, Institute for Vaccine Safety, 615 N Wolfe
St, Rm 5515, Baltimore, MD 21205. E-mail: nhalsey@jhsph.edu
ABBREVIATIONS
AAP, American Academy of Pediatrics; USPHS, US Public Health Service; HBsAg,
hepatitis B surface antigen; NRC, National Research Council; RfD, reference
dose; FDA, Food and Drug Administration.
 


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11746429&dopt=Abstract

 
J Neurosci Res 2001 Dec 1;66(5):998-1002 Related Articles, Books, LinkOut
Click here to read 
Identification and characterization of uptake systems for cystine and cysteine in cultured astrocytes and neurons: evidence for methylmercury-targeted disruption of astrocyte transport.

Shanker G, Aschner M.

Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1083, USA.

Maintenance of appropriate intracellular glutathione (GSH) levels is crucial for cellular defense against oxidative damage. A suggested mechanism of methylmercury (MeHg) neurotoxicity implicates the involvement of oxygen radical formation and a decrease in cellular levels of GSH. Astrocytes play an important role in providing GSH precursors to neurons, and as will be discussed in this review, altered GSH homeostasis likely leads to impairment of astrocytic handling of glutamate, and neuronal energy metabolism. The review summarizes recent observations on transport systems for cysteine and cystine, precursors of GSH, in primary cultures of astrocytes and neurons, and their sensitivity to MeHg treatment. Copyright 2001 Wiley-Liss, Inc.

Publication Types:
  • Review
  • Review, Tutorial


PMID: 11746429 [PubMed - indexed for MEDLINE]


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11470315&dopt=Abstract

 
Brain Res Bull 2001 May 15;55(2):197-203 Related Articles, Books, LinkOut
Click here to read 
Neurotoxicity and molecular effects of methylmercury.

Castoldi AF, Coccini T, Ceccatelli S, Manzo L.

University of Pavia and "Salvatore Maugeri" Foundation, Pavia, Italy. acastoldi@fsm.it

The neurotoxicity of high levels of methylmercury (MeHg) and the high susceptibility of the developing brain are well established both in humans and experimental animals. Prenatally poisoned children display a range of effects varying from severe cerebral palsy to subtle developmental delays. Still unknown is the lowest dose that impairs neurodevelopment. The primary source of human exposure is the fish. The data obtained so far from epidemiological studies on fish-eating populations are not consistent. A reference dose of 0.1 microg MeHg/kg per day has been established by the U.S. Environmental Protection Agency based on a study on Iraqi children exposed to MeHg in utero. However, these exposures occurred at high level for a limited period of time, and consequently were not typical of lower chronic exposure levels associated with fish consumption. Major obstacles for estimation of a threshold dose for MeHg include the delayed appearance of the neurodevelopmental effects following prenatal exposure and limited knowledge of cellular and molecular processes underlying these neurological changes. In this respect, a strategy which aims at identifying sensitive molecular targets of MeHg at environmentally relevant levels may prove particularly useful to risk assessment. Here some examples of MeHg molecular effects occurring at low doses/concentrations are presented.

Publication Types:
  • Review
  • Review, Tutorial


PMID: 11470315 [PubMed - indexed for MEDLINE]


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11578608&dopt=Abstract

 
: Brain Res 2001 Sep 28;914(1-2):159-65 Related Articles, Books, LinkOut
Click here to read 
Methylmercury inhibits cysteine uptake in cultured primary astrocytes, but not in neurons.

Shanker G, Allen JW, Mutkus LA, Aschner M.

Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1083, USA.

The maintenance of adequate intracellular glutathione (GSH) concentrations is dependent on the availability and transport of the rate-limiting substrate, cysteine. A suggested mechanism of methylmercury (MeHg) neurotoxicity in brain involves the formation of oxygen radicals, and a decrease in intracellular levels of GSH. Recently, we have characterized various cysteine transport systems (both Na(+)-dependent and -independent) in cerebrocortical astrocytes and hippocampal neurons. The present study was carried out to investigate the effect of MeHg on cysteine uptake in both astrocytes and neurons, and to determine whether cysteine transport is differentially affected in the two cell types by MeHg treatment. Sixty-minute pretreatment with MeHg caused significant concentration-dependent inhibition in cysteine uptake in astrocytes, but not in neurons. As most of the cysteine transport is Na(+)-dependent (80-90% of total), additional studies focused on MeHg's effect on the Na(+)-dependent cysteine transporters X(AG(-)) and ASC. An additive inhibitory effect on cysteine uptake was observed in astrocytes treated with MeHg (5 microM) plus sub-maximal inhibitory concentrations (0.1 and 0.5 mM) of threo-beta-hydroxy-aspartate (THA), a specific inhibitor of the Na(+)-dependent transporter, X(AG(-)), compared to astrocytes treated with MeHg (P<0.001) or THA alone (P<0.05). There was no additive effect of MeHg and maximal inhibitory concentrations of THA (1.0 and 5.0 mM) on astrocytic cysteine uptake inhibition. Additional studies examined the sensitivity of the Na(+)-dependent ASC transport system to MeHg treatment. Maximal inhibitory concentration of L-serine (10 mM) alone had a rather modest inhibitory effect on cysteine uptake, and when applied in the presence of MeHg there was no additive effect. These results suggest that the inhibition of cysteine uptake by MeHg in astrocytes occurs through specific inhibition of both the X(AG(-)) as well as the ASC transport system.

PMID: 11578608 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11482002&dopt=Abstract

 
Perspect Biol Med 2001 Summer;44(3):315-32 Related Articles, Books, LinkOut

Abraham Lincoln's blue pills. Did our 16th president suffer from mercury poisoning?

Hirschhorn N, Feldman RG, Greaves IA.

Boston University School of Medicine, USA. bertzpoet@yahoo.com

It is well known that Abraham Lincoln took a medicine called "blue mass" or "blue pill," commonly prescribed in the 19th century. What is now hardly known is that the main ingredient of blue mass was finely dispersed elemental mercury. As his friends understood, mercury was often prescribed for melancholy or "hypochondriasis," a condition Lincoln famously endured. Mercury in the form of the blue pill is a potential neurotoxin, which we have demonstrated by recreating and testing the recipe. We present the testimony of many of Lincoln's contemporaries to suggest that Lincoln suffered the neurobehavioural consequences of mercury intoxication but, perhaps crucial to history, before the main years of his presidency; he was astute enough to recognize the effects and stop the medication soon after his inauguration.

Publication Types:
  • Biography
  • Historical Article


Personal Name as Subject:

  • Lincoln A


PMID: 11482002 [PubMed - indexed for MEDLINE]


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11339848&dopt=Abstract

 
: Med Hypotheses 2001 Apr;56(4):462-71 Related Articles, Books, LinkOut
Click here to read 
Autism: a novel form of mercury poisoning.

Bernard S, Enayati A, Redwood L, Roger H, Binstock T.

ARC Research, Cranford, New Jersey 07901, USA.

Autism is a syndrome characterized by impairments in social relatedness and communication, repetitive behaviors, abnormal movements, and sensory dysfunction. Recent epidemiological studies suggest that autism may affect 1 in 150 US children. Exposure to mercury can cause immune, sensory, neurological, motor, and behavioral dysfunctions similar to traits defining or associated with autism, and the similarities extend to neuroanatomy, neurotransmitters, and biochemistry. Thimerosal, a preservative added to many vaccines, has become a major source of mercury in children who, within their first two years, may have received a quantity of mercury that exceeds safety guidelines. A review of medical literature and US government data suggests that: (i) many cases of idiopathic autism are induced by early mercury exposure from thimerosal; (ii) this type of autism represents an unrecognized mercurial syndrome; and (iii) genetic and non-genetic factors establish a predisposition whereby thimerosal's adverse effects occur only in some children. Copyright 2001 Harcourt Publishers Ltd.

Publication Types:
  • Review
  • Review, Academic


PMID: 11339848 [PubMed - indexed for MEDLINE]

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11770890&dopt=Abstract

 
: Neurotoxicology 2001 Oct;22(5):691-7 Related Articles, Books, LinkOut

Predicted mercury concentrations in hair from infant immunizations: cause for concern.

Redwood L, Bernard S, Brown D.

Coalition for Safe Minds, Cranford, NJ 07016, USA. tlredwood@mindspring.com

Mercury (Hg) is considered one of the worlds most toxic metals. Current thinking suggests that exposure to mercury occurs primarily from seafood contamination and rare catastrophic events. Recently, another common source of exposure has been identified. Thimerosal (TMS), a preservative found in many infant vaccines, contains 49.6% ethyl mercury (EtHg) by weight and typically contributes 25 microg of EtHg per dose of infant vaccine. As part of an ongoing review, the Food and Drug Administration (FDA) announced in 1999 that infants who received multiple TMS-preserved vaccines may have been exposed to cumulative Hg in excess of Federal safety guidelines. According to the centers for disease control (CDC) recommended immunization schedule, infants may have been exposed to 12.5 microg Hg at birth, 62.5 microg EtHg at 2 months, 50 microg EtHg at 4 months, 62.5 microg EtHg at 6 months, and 50 microg EtHg at approximately 18 months, for a total of 237.5 microg EtHg during the first 18 months of life, if all TMS-containing vaccines were administered. Neurobehavioral alterations, especially to the more susceptible fetus and infant, are known to occur after relatively low dose exposures to organic mercury compounds. In effort, to further elucidate the levels of ethyl mercury resulting from exposure to vaccinal TMS, we estimated hair Hg concentrations expected to result from the recommended CDC schedule utilizing a one compartment pharmacokinetic model. This model was developed to predict hair concentrations from acute exposure to methymercury (MeHg) in fish. Modeled hair Hg concentrations in infants exposed to vaccinal TMS are in excess of the Environmental Protection Agency (EPA) safety guidelines of 1 ppm for up to 365 days, with several peak concentrations within this period. More sensitive individuals and those with additional sources of exposure would have higher Hg concentrations. Given that exposure to low levels of mercury during critical stages of development has been associated with neurological disorders in children, including ADD, learning difficulties, and speech delays, the predicted hair Hg concentration resulting from childhood immunizations is cause for concern. Based on these findings, the impact which vaccinal mercury has had on the health of American children warrants further investigation.

PMID: 11770890 [PubMed - indexed for MEDLINE]

AN:  21626817


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11331700&dopt=Abstract

 
Pediatrics 2001 May;107(5):1147-54 Related Articles, Books, LinkOut

Comment in:

Click here to read 
An assessment of thimerosal use in childhood vaccines.

Ball LK, Ball R, Pratt RD.

Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Foodand Drug Administration, Rockville, Maryland 20852, USA. balll@cber.fda.gov

BACKGROUND: On July 7, 1999, the American Academy of Pediatrics and the US Public Health Service issued a joint statement calling for removal of thimerosal, a mercury-containing preservative, from vaccines. This action was prompted in part by a risk assessment from the Food and Drug Administration that is presented here. METHODS: The risk assessment consisted of hazard identification, dose-response assessment, exposure assessment, and risk characterization. The literature was reviewed to identify known toxicity of thimerosal, ethylmercury (a metabolite of thimerosal) and methylmercury (a similar organic mercury compound) and to determine the doses at which toxicity occurs. Maximal potential exposure to mercury from vaccines was calculated for children at 6 months old and 2 years, under the US childhood immunization schedule, and compared with the limits for mercury exposure developed by the Environmental Protection Agency (EPA), the Agency for Toxic Substance and Disease Registry, the Food and Drug Administration, and the World Health Organization. RESULTS: Delayed-type hypersensitivity reactions from thimerosal exposure are well-recognized. Identified acute toxicity from inadvertent high-dose exposure to thimerosal includes neurotoxicity and nephrotoxicity. Limited data on toxicity from low-dose exposures to ethylmercury are available, but toxicity may be similar to that of methylmercury. Chronic, low-dose methylmercury exposure may cause subtle neurologic abnormalities. Depending on the immunization schedule, vaccine formulation, and infant weight, cumulative exposure of infants to mercury from thimerosal during the first 6 months of life may exceed EPA guidelines. CONCLUSION: Our review revealed no evidence of harm caused by doses of thimerosal in vaccines, except for local hypersensitivity reactions. However, some infants may be exposed to cumulative levels of mercury during the first 6 months of life that exceed EPA recommendations. Exposure of infants to mercury in vaccines can be reduced or eliminated by using products formulated without thimerosal as a preservative.

Publication Types:

  • Review
  • Review, Tutorial


PMID: 11331700 [PubMed - indexed for MEDLINE]

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11480489&dopt=Abstract

 
: Drug Saf 2001;24(8):567-74 Related Articles, Books, LinkOut

Thiomersal in vaccines: is removal warranted?

Clements CJ, Ball LK, Ball R, Pratt RD.

Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. clementscj@who.ch

The mercury-based vaccine preservative thiomersal has come under scrutiny in recent months because of its presence in certain vaccines that provide the foundation of childhood immunisation schedules. Over the past decade new vaccines have been added to the recommended childhood schedule, and the relatively smaller bodyweight of infants has led to concern that the cumulative exposure of mercury from infant vaccines may exceed certain guidelines for the human consumption of mercury. In the US, government agencies and professional societies have recently recommended that thiomersal be removed altogether from vaccines. Some involved in developing vaccine policy feel that the evidence to support these safety concerns has not risen to the level required for such a response. This apparent divergence of opinion has left healthcare professionals and the public with uncertainty about the potential health effects from low level exposure to thiomersal as well as the necessity of removing thiomersal from vaccines. At present, scientific investigation has not found conclusive evidence of harm from thiomersal in vaccines. As a precautionary measure, efforts are under way to remove or replace thiomersal from vaccines and providers should anticipate the availability of more vaccine products that are thiomersal-free over the coming years.
 

Publication Types:

  • Review
  • Review, Tutorial


PMID: 11480489 [PubMed - indexed for MEDLINE]

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10770336&dopt=Abstract

 
Lancet 2000 Apr 8;355(9211):1279-80 Related Articles, Books, LinkOut

Thiomersal in vaccines.

Clements CJ, Ball LK, Ball R, Pratt D.

Publication Types:
  • Letter


PMID: 10770336 [PubMed - indexed for MEDLINE]

From the article:  "While much remains to be understood about the implications of various concentrations, it seems that some infants may receive doses of mercury from vaccines that, while not obviously toxic, may be of concern and are in breach of various agency recommendations."

AN:  21372801


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10802503&dopt=Abstract

 
J Pediatr 2000 May;136(5):679-81 Related Articles, Books, LinkOut

Comment in:

Click here to read 
Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants.

Stajich GV, Lopez GP, Harry SW, Sexson WR.

Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341, USA.

Thimerosal, a derivative of mercury, is used as a preservative in hepatitis B vaccines. We measured total mercury levels before and after the administration of this vaccine in 15 preterm and 5 term infants. Comparison of pre- and post-vaccination mercury levels showed a significant increase in both preterm and term infants after vaccination. Additionally, post-vaccination mercury levels were significantly higher in preterm infants as compared with term infants. Because mercury is known to be a potential neurotoxin to infants, further study of its pharmacodynamics is warranted.

PMID: 10802503 [PubMed - indexed for MEDLINE]

AN:  20263990


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10802490&dopt=Abstract

 
J Pediatr 2000 May;136(5):599-605 Related Articles, Books, LinkOut

Comment in:

Click here to read 
Maternal seafood diet, methylmercury exposure, and neonatal neurologic function.

Steuerwald U, Weihe P, Jorgensen PJ, Bjerve K, Brock J, Heinzow B, Budtz-Jorgensen E, Grandjean P.

Faeroese Hospital System, Thorshavn, Faeroe Islands.

OBJECTIVE: To determine whether neonatal neurologic function is adversely affected by seafood contaminants from maternal diet during pregnancy. STUDY DESIGN: One hundred eighty-two singleton term births were evaluated in the Faeroe Islands, where marine food includes pilot whale. Maternal serum, hair, and milk and umbilical cord blood were analyzed for contaminants. Levels of essential fatty acids, selenium, and thyroid hormones were determined in cord blood. Each infant's neurologic optimality score was determined at 2 weeks of age adjusted for gestational age, and predictors were assessed by regression analysis. RESULTS: Exposures to methylmercury and polychlorinated biphenyls were increased in relation to maternal seafood intake, as were omega3 fatty acid concentrations in cord serum. Thyroid function was normal. After adjustment for confounders, a 10-fold increase of the cord-blood mercury concentration was associated with a decreased neurologic optimality score of 2.0 (P =. 03). This effect corresponds to a decrease in gestational age of about 3 weeks. Other indicators of the seafood diet had no effect on this outcome. CONCLUSIONS: Prenatal exposure to methylmercury from contaminated seafood was associated with an increased risk of neurodevelopmental deficit. Thus in this North Atlantic population, methylmercury constituted an important neurologic risk factor, although effects of other seafood components were not detectable.

PMID: 10802490 [PubMed - indexed for MEDLINE]


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10906032&dopt=Abstract

 
Arch Dis Child 2000 Aug;83(2):174-5 Related Articles, Books, LinkOut
Click here to read 
Mercury intoxication presenting with tics.

Li AM, Chan MH, Leung TF, Cheung RC, Lam CW, Fok TF.

Department of Paediatrics, The Chinese University of Hong Kong, 6th Floor, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong SAR, China. Albertm68mcli@yahoo.com

A 5 year old Chinese boy presented with recurrent oral ulceration followed by motor and vocal tics. The Chinese herbal spray he used for his mouth ulcers was found to have a high mercury content. His blood mercury concentration was raised. Isolated tics as the sole presentation of mercury intoxication has not previously been reported.

PMID: 10906032 [PubMed - indexed for MEDLINE]
 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10912926&dopt=Abstract

 
Acta Neuropathol (Berl) 2000 Jul;100(1):95-100 Related Articles, Books, LinkOut
Click here to read 
Neuron loss in cerebellar cortex of rats exposed to mercury vapor: a stereological study.

Sorensen FW, Larsen JO, Eide R, Schionning JD.

Department of Neurobiology, Institute of Anatomy, University of Aarhus, Denmark. u920932@svfedb.aau.dk

Mercury vapor produces tremor in humans and experimental animals. We have previously reported that mercury vapor intoxication over an 8-week period induces only subtle changes in dorsal root ganglia and nerve roots in rats. In the present study we have carried out stereological analyses of the cerebellum of the same rats, and demonstrated significant losses of Purkinje cells (12.7%, 2P = 0.005) and granule cells (15.6%, 2P = 0.016). All sizes of Purkinje cells were lost with an equal probability, i.e. there were no indication of any preferential loss of any subpopulation of the neurons. The volume of the granular cell layer was significantly reduced (18.9%, 2P = 0.0 15), whereas the volumes of the molecular layer and the white matter were unchanged. Previous stereological studies have demonstrated that methyl mercury intoxication primarily induces degeneration in the peripheral nervous system, while sparing the cerebellum. We therefore suggest that metallic mercury vapor and methyl mercury have different toxicological profiles in rats, where metallic mercury vapor mainly affects the central nervous system and methyl mercury mainly affects the peripheral nervous system.

PMID: 10912926 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11022856&dopt=Abstract

 
: Neurotoxicology 2000 Aug;21(4):459-74 Related Articles, Books, LinkOut

Residual neurologic deficits 30 years after occupational exposure to elemental mercury.

Letz R, Gerr F, Cragle D, Green RC, Watkins J, Fidler AT.

Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. rletz@sph.emory.edu

A battery of tests of peripheral and central nervous system function was administered to 205 former workers of a large heavy industrial plant, 104 of whom were previously exposed to inorganic mercury. The mean age of those examined was 71 years. Exposed subjects had participated in a urine-mercury exposure monitoring program during the time of operation of a process that required the use of mercury and its subsequent clean-up. Mercury exposure had been high (mean peak urine mercury concentration was >600 microg/l) and had ended 30 years or more prior to the investigation. Peripheral nerve function outcomes that were statistically significantly associated with cumulative mercury exposure after controlling for covariates included classification as having peripheral neuropathy, peroneal motor nerve conduction velocity, ulnar motor nerve conduction velocity, and peroneal motor nerve F-wave latency. Quantitative assessment of resting tremor was nearly significantly associated with cumulative mercury exposure (p=0.07). Among tests of central nervous system function, results of the Handeye Coordination test were significantly associated with cumulative mercury exposure after controlling for covariates. Cumulative mercury exposure was not observed to be associated with a quantitative measure of dementia or with a number of cognitive neurobehavioral test outcomes. The statistically significant associations with mercury exposure were observed in spite of greater mortality among the exposed group than the unexposed group. These results suggest that substantial occupational mercury exposure can have long-term adverse effects on the peripheral nervous system detectable decades after cessation of exposure. Such long-term adverse effects were not observed for a measure of dementia or other measures of cognitive function.

PMID: 11022856 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10719069&dopt=Abstract

 
Brain Res 2000 Mar 24;859(2):233-9 Related Articles, Books, LinkOut
Click here to read 
Distinct pattern of neuronal degeneration in the fetal rat brain induced by consecutive transplacental administration of methylmercury.

Kakita A, Wakabayashi K, Su M, Sakamoto M, Ikuta F, Takahashi H.

Department of Pathology, Brain Research Institute, Niigata University, 1 Asahimachi, Niigata, Japan. kakita@bri.niigata-u.ac.jp

The transplacental neurotoxicity of methylmercury (MeHg) on the fetal rat brain was studied. Adult female rats were administered 1, 2 or 3 mg/kg/day methylmercury chloride (MMC) orally for either 5 or 12 days, and were then mated. They were subsequently administered MMC in the same manner until the end of gestation. On embryonic day 22, a proportion of the fetal brains were histologically examined. Neuronal degeneration of varying degree was detected consistently in the brain stem, cingulate cortex, thalamus and cerebral basal area, including the hypothalamus. The distribution pattern of neuronal damage was different from those in rats treated with MeHg in the postnatal or adult stages. This finding suggests that pathomechanisms in MeHg intoxication operate distinctively in the fetal brain. The offspring derived from dams treated with 1 mg/kg/day MMC for 5 pregestational days and throughout pregnancy survived with inherent brain lesions. This experimental model could be a useful tool for research on the neurotoxicity of MeHg in the human fetal brain.

PMID: 10719069 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10568650&dopt=Abstract

 
JAMA 1999 Nov 10;282(18):1763-6 Related Articles, Books, LinkOut

Comment in:


Comment on:


Limiting infant exposure to thimerosal in vaccines and other sources of mercury.

Halsey NA.

Publication Types:

  • Comment
  • Editorial

From the article: 

"Exposure to ethylmercury from vaccines containing thimerosal in the first 6 monts of life ranges from 0 to 187 micrograms based on which vaccines are administered.  Since many vaccines do not contain thimerosal, most children receive less than the total amount of mercury indicated in the guidelines during the first 6 months of life.  If all thimerosal-containing vaccines are given, the total exposures exceed the EPA guidelines, and possibly other guidelines, for the smallest infants.  There are safety or uncertainty factors (10-fold for the EPA) built into the guidelines, and experts believe there is no evidence of harm from exposure to thimerosal in vaccines.  However, clinicians are uncertain as to how much mercury can be safely given at 1 time when multiple thimerosal-containing vaccines are administered simultaneously.

Data from 2 recent studies examining the relationship between methylmercury exposure and neuropsychological outcome in children suggest that intermittent large exposures may pose more risk than small daily doses."


PMID: 10568650 [PubMed - indexed for MEDLINE]

AN:  20033298


Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.
 

 

Date: 
June 28, 2002